Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Clinical trial NCT04490421 · UNKNOWN
Trial details
- NCT number
- NCT04490421
- Sponsor
- Fuzhou General Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2021-08-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.